Gildess 1.5/30

Endometriosis, Low Testosterone, Osteoporosis + 16 more
Treatment
20 Active Studies for Gildess 1.5/30

What is Gildess 1.5/30

NorethisteroneThe Generic name of this drug
Treatment SummaryEthinylestradiol was developed in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was created to be a more effective form of estrogen when taken orally. This was achieved by adding an ethinyl group to estradiol. Ethinylestradiol is now commonly used in contraceptive pills and was approved by the FDA in 1943.
Neconis the brand name
image of different drug pills on a surface
Gildess 1.5/30 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Necon
Norethisterone
1967
347

Effectiveness

How Gildess 1.5/30 Affects PatientsEthinylestradiol is a hormone-based drug that stops the body from releasing certain hormones that cause ovulation and thickening of the uterus lining. It lasts a long time and is taken once daily, and it is generally considered safe with few serious side effects. However, patients should be aware of the risk of blood clots.
How Gildess 1.5/30 works in the bodyEthinylestradiol is a synthetic hormone that acts like estrogen. It affects the body in many ways, including reducing bone density. When taken as a contraceptive, it prevents pregnancy by stopping ovulation, making it difficult for sperm to travel to the egg, and preventing changes in the endometrium that are necessary for a fertilized egg to attach. Ethinylestradiol also lowers luteinizing hormone levels, which reduces the blood supply to the endometrium, and increases the amount of sex hormone binding globulin.

When to interrupt dosage

The measure of Gildess 1.5/30 is contingent upon the recognized condition, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The quantity of dosage depends on the method of delivery indicated in the table underneath.
Condition
Dosage
Administration
Atrophic
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Oral Contraceptives
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
hypoestrogenism
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Fracture
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hot flashes
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Estrogen Deprivation Symptoms
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Osteoporosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Birth Control
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Therapeutic procedure
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Low Testosterone
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Osteoporosis, Postmenopausal
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Primary Ovarian Insufficiency
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hormonal Contraception
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Menopause
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
female castration
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hormone Replacement Therapy
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Vasomotor System
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Gildess 1.5/30 Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Norethisterone may interact with Pulse Frequency
Liver Diseases
Do Not Combine
Thrombophilia
Do Not Combine
Vaginal Hemorrhage
Do Not Combine
Malignant Neoplasms
Do Not Combine
Benign hepatic neoplasm
Do Not Combine
Breast Cancer
Do Not Combine
Thromboembolism
Do Not Combine
There are 20 known major drug interactions with Gildess 1.5/30.
Common Gildess 1.5/30 Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Norethisterone.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Norethisterone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.
Clomipramine
Major
The metabolism of Clomipramine can be increased when combined with Norethisterone.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Norethisterone.
Gildess 1.5/30 Toxicity & Overdose RiskWomen who overdose on birth control pills may experience bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue. Treatment for an overdose should include monitoring for electrolyte levels and signs of acidosis, in addition to providing symptomatic and supportive care.
image of a doctor in a lab doing drug, clinical research

Gildess 1.5/30 Novel Uses: Which Conditions Have a Clinical Trial Featuring Gildess 1.5/30?

There are 38 active studies evaluating the potential of Gildess 1.5/30 to facilitate Folate supplementation therapy, reduce Premenstrual Dysphoric Disorder symptoms and provide relief for Menopausal women.
Condition
Clinical Trials
Trial Phases
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Oral Contraceptives
1 Actively Recruiting
Not Applicable
Endometriosis
27 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Endometriosis
2 Actively Recruiting
Phase 4, Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Estrogen Deprivation Symptoms
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
female castration
0 Actively Recruiting
Atrophic
4 Actively Recruiting
Phase 4, Not Applicable
Hormone Replacement Therapy
0 Actively Recruiting
Hormonal Contraception
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
Fracture
0 Actively Recruiting
Vasomotor System
0 Actively Recruiting
Primary Ovarian Insufficiency
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Menopause
0 Actively Recruiting

Gildess 1.5/30 Reviews: What are patients saying about Gildess 1.5/30?

4Patient Review
10/12/2016
Gildess 1.5/30 for Painful Periods
I was switched to Gildess after Junel was discontinued. I found myself to be very emotional, spacey, and anxious on this new medication. I cried a lot and got frustrated easily. My period was normal and on time, which was good. But I didn't like the other side effects, so I'm hoping to try something else soon.
3Patient Review
4/29/2013
Gildess 1.5/30 for Birth Control
The side effects on this medication are really severe. I've never experienced anything like this with any other birth control, so I'm going back to my old one.
1Patient Review
9/18/2014
Gildess 1.5/30 for Birth Control
Do not take this medication. You will have your period twice a month, and experience bad side effects. I thought maybe it would regulate after 2 months, and the side effects did not stop. This has been a frustrating experience, avoid this medication.
1Patient Review
12/1/2013
Gildess 1.5/30 for Birth Control
In my experience, this treatment made me break out more, caused weight gain, and increased my levels of depression and anxiety. Overall, a terrible experience.
1Patient Review
10/18/2013
Gildess 1.5/30 for Birth Control
I started taking this drug and after only two weeks, I began experiencing serious negative side effects like crying spells, depression, and panic attacks. I had to stop taking the medication and my doctor put me on a different one. In my opinion, Gildess is not worth the risk.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gildess 1.5/30

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Microgestin a brand name?

"There are many brand names for this medication. Some examples include Aurovela 1/20, Aurovela 1.5/30, Aurovela 24 Fe, Aurovela Fe 1/20, Aurovela Fe 1.5/30, Blisovi 24 Fe, Blisovi Fe 1/20, Blisovi Fe 1.5/30, Femhrt, Femhrt 1/5, Fyavolv, Estrostep Fe, Hailey 1.5/30, Hailey Fe 1.5/30, Hailey 24 Fe."

Answered by AI

What is Larin generic for?

"Microgestin 1/20 is a medication that prevents pregnancy in women by combining two drugs, ethinyl estradiol and norethindrone. The generic version of this drug, known as ethinyl estradiol/norethindrone, costs an average of $109 for a supply of 126 tablets."

Answered by AI

What is Gildess used to treat?

"This hormone medication, which contains a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen), is used as a means of contraception to prevent pregnancy."

Answered by AI

What is Gildess Fe?

"This medication helps to prevent ovulation and pregnancy by combining the hormones estrogen and progestin. It may also be used to treat acne."

Answered by AI

Clinical Trials for Gildess 1.5/30

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH
The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.
Phase 4
Waitlist Available
University Hospitals Cleveland Medical CenterAdi Cosic, DO
Have you considered Gildess 1.5/30 clinical trials? We made a collection of clinical trials featuring Gildess 1.5/30, we think they might fit your search criteria.Go to Trials
Have you considered Gildess 1.5/30 clinical trials? We made a collection of clinical trials featuring Gildess 1.5/30, we think they might fit your search criteria.Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA
The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Wear an optional fitness tracker to collect data on sleep, movement, and heart rate variability 5. Be followed for 60 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.
Recruiting
Online Trial
Alethios, Inc.Nirav Shah, MD, MPHSamphire Group, Inc.
Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Have you considered Gildess 1.5/30 clinical trials? We made a collection of clinical trials featuring Gildess 1.5/30, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security